Lilly's Solanezumab Miss Is Another Setback in Alzheimer's

Early Friday, Eli Lilly and Co. reported that Phase III Alzheimer's candidate solanezumab missed both the cognitive and functional endpoints in its two double-blind, placebo-controlled EXPEDITION trials in patients with mild-to-moderate disease.

The monoclonal antibody binds specifically to soluble amyloid beta and is aimed at drawing the peptide away from the brain through the blood.